BioFocus announced today that it has signed
a collaboration agreement with The Michael J. Fox Foundation for
Parkinson's Research,
a not-for-profit organization focused on developing therapies for Parkinson's
disease. Under the agreement, BioFocus
will perform fragment-based screening, assay development and hit-finding programs,
to identify compounds that have the basis for a novel Parkinson's disease
diagnostic test.
"We are delighted to have the opportunity to
support The Michael J. Fox Foundation in its development of improved therapies
for those living with Parkinson's," said Dr Kate Hilyard, VP Biological
Sciences. "The collaboration will
utilize BioFocus' biology platform that delivers drug discovery solutions
through its experienced teams and state-of-the-art technologies".
About
The Michael J. Fox Foundation for Parkinson's Research
As the world's largest private funder of
Parkinson's research, The Michael J. Fox Foundation is dedicated to
accelerating a cure for Parkinson's disease and improved therapies for those
living with the condition today. The Foundation pursues its goals through an
aggressively funded, highly targeted research program coupled with active
global engagement of scientists, Parkinson's patients, business leaders,
clinical trial participants, donors and volunteers. In addition to funding over
$240 million in research to date, the Foundation has fundamentally altered the
trajectory of progress toward a cure. Operating at the hub of worldwide
Parkinson's research, the Foundation forges groundbreaking collaborations with
industry leaders, academic scientists and government research funders;
increases Parkinson's awareness through high-profile advocacy, events and
outreach; and coordinates the grassroots involvement of thousands of Team Fox
members around the world.
About BioFocus
BioFocus
delivers drug discovery solutions through a comprehensive platform run by
dedicated teams with a track record in gene-to-clinical candidate
discovery. BioFocus' offering includes
target discovery in human primary cells, focused as well as diverse compound
libraries,
in vitro and cell-based
screening, structural biology, medicinal chemistry and ADME/PK services,
supported by unique chemogenomic and informatics tools. As a service division of Galapagos, BioFocus
has over 210 employees with research facilities in three countries. More information at:
www.biofocus.com.
BioFocus
® and SilenceSelect
® are trademarks of
Galapagos NV and/or its affiliates © Copyright 2011 Galapagos NV.
